Adial Pharmaceuticals Inc (NASDAQ: ADIL)’s stock price has increased by 71.69 compared to its previous closing price of 1.13. However, the company has seen a 56.46% increase in its stock price over the last five trading sessions. Accesswire reported 2024-02-15 that CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024. Cary Claiborne, Chief Executive Officer of Adial, is scheduled to present on Tuesday, February 20 at 11:30 a.m.
Is It Worth Investing in Adial Pharmaceuticals Inc (NASDAQ: ADIL) Right Now?
Additionally, the 36-month beta value for ADIL is 1.54. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ADIL is 3.67M and currently, short sellers hold a 0.24% ratio of that float. The average trading volume of ADIL on April 10, 2024 was 4.01M shares.
ADIL’s Market Performance
ADIL stock saw a decrease of 56.46% in the past week, with a monthly decline of -3.00% and a quarterly a decrease of 13.92%. The volatility ratio for the week is 9.54%, and the volatility levels for the last 30 days are 14.38% for Adial Pharmaceuticals Inc (ADIL). The simple moving average for the last 20 days is 32.91% for ADIL stock, with a simple moving average of -31.70% for the last 200 days.
Analysts’ Opinion of ADIL
Many brokerage firms have already submitted their reports for ADIL stocks, with Maxim Group repeating the rating for ADIL by listing it as a “Buy.” The predicted price for ADIL in the upcoming period, according to Maxim Group is $5 based on the research report published on October 30, 2018 of the previous year 2018.
ADIL Trading at 33.32% from the 50-Day Moving Average
After a stumble in the market that brought ADIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.14% of loss for the given period.
Volatility was left at 14.38%, however, over the last 30 days, the volatility rate increased by 9.54%, as shares surge +4.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +59.68% upper at present.
During the last 5 trading sessions, ADIL rose by +59.68%, which changed the moving average for the period of 200-days by -64.00% in comparison to the 20-day moving average, which settled at $1.4638. In addition, Adial Pharmaceuticals Inc saw 4.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADIL starting from Schuyler Kevin, who purchase 700 shares at the price of $2.74 back on Sep 29 ’23. After this action, Schuyler Kevin now owns 700 shares of Adial Pharmaceuticals Inc, valued at $1,918 using the latest closing price.
Stock Fundamentals for ADIL
The total capital return value is set at -1.85. Equity return is now at value -208.36, with -144.46 for asset returns.
Currently, EBITDA for the company is -6.89 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
In conclusion, Adial Pharmaceuticals Inc (ADIL) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
